Not Yet Recruiting Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial NCT07576725 Conditions Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +119 more Locations Uganda Cancer Institute — Kampala, Uganda View Trial Details
Active, Not Recruiting Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV NCT04514484 Conditions Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more Locations Northwestern University — Chicago, Illinois, United States Montefiore Medical Center-Einstein Campus — The Bronx, New York, United States University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania, United States View Trial Details
